久久视频在线视频精品-日韩亚洲变态另类中文-free性欧美69巨大-mm131巨爆乳美女少妇动态图

Shanghai, China – On November 17, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort?") announced that its subsidiary MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort? Endovascular") was listed as "2016 Shanghai Science and Technology Little Giant Enterprise (for Cultivation)" by Science and Technology Commission of Shanghai Municipality and Shanghai Municipal Commission of Economy and Informatization. The selected company will gain funding from city or district (county) governments based on the companies' independent innovation plans. Founded in 2010 and 2013 in Shanghai, MicroPort? Endovascular primarily focus on the development, manufacture, and marketing of the interventional medical devices respectively for the treatment of electrophysiological diseases, and peripheral-vascular- and endovascular-related diseases. Its device is widely used in China's top hospitals and has been exported to many overseas countries and regions. MicroPort? Endovascular was selected as 2015 Shanghai High- and New-Technology Enterprise.

MicroPort? Chief Technology Officer Dr. Qiyi Luo said:" MicroPort? will always stick to its unique innovative R&D philosophy and focus on creating core independent intellectual properties. As the subsidiary is listed as 'Shanghai Science and Technology Little Giant Enterprise (for Cultivation)' it shows the government's recognition on the innovative capabilities and core technology R&D of MicroPort? Endovascular, which will definitely fuels its motivation for innovation. In the future, the company will further enhance its innovation capabilities, increase the input in R&D, to drive its developments."

Under the direction of Science and Technology Commission of Shanghai Municipality and Shanghai Municipal Commission of Economy and Informatization, the Science and Technology Little Giant Project aims to provide support to unlisted high-tech SMEs (small- and medium-sized enterprises) registered in Shanghai so as to foster the strategic and emerging industries such as information technology, smarter healthcare and bio-tech industries. The candidate has to meet strict requirements regarding the percentage of its R&D headcount, its R&D expenses in recent three fiscal years, its major business revenue in the previous year, the average growth rate of its revenue or net profit in the previous three years, management team and finical regulations. It will be further assessed through oral defense and online review before eventually be selected as "2016 Shanghai Science and Technology Little Giant Enterprise."